IP Library › Granted Patent US 12,459,937
Granted Patent B2
US 12,459,937 · App. 19/091,638 · Granted Nov 4, 2025

Fused imidazole derivative, preparation method therefor, and medical use thereof

Inventors: Fanglong Yang (Shanghai, CN); Ling Zhang (Shanghai, CN); Liangliang Zheng (Shanghai, CN); Feng He (Shanghai, CN); Weikang Tao (Shanghai, CN)
Assignee: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
C07D417/14A61P1/16C07D405/14C07D471/04C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,459,937
App. No.
19/091,638
Granted
Nov 4, 2025
Kind
B2
Abstract

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Claims (28)

1 . A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7 . A compound, which is:

or a pharmaceutically acceptable salt thereof.

8 . The compound of claim 7 , which is:

9 . A compound, which is:

or a pharmaceutically acceptable salt thereof.

10 . The compound of claim 9 , which is:

11 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

12 . A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

13 . A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

14 . A pharmaceutical composition comprising the compound of claim 4 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

15 . A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

16 . A pharmaceutical composition comprising the compound of claim 6 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

17 . A pharmaceutical composition comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

18 . A pharmaceutical composition comprising the compound of claim 8 , and one or more pharmaceutically acceptable carriers, diluents or excipients.

19 . A pharmaceutical composition comprising the compound of claim 9 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

20 . A pharmaceutical composition comprising the compound of claim 10 , and one or more pharmaceutically acceptable carriers, diluents or excipients.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: YANG, FANGLONG; ZHANG, LING; ZHENG, LIANGLIANG; HE, FENG; TAO, WEIKANG
To: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
Reel/Frame 071408/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
To: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
Reel/Frame 071408/0336 →
Priority Claims (6)
CN 202010905693.4 · Sep 1, 2020 · national
CN 202010984336.1 · Sep 18, 2020 · national
CN 202011124085.6 · Oct 20, 2020 · national
CN 202011253077.1 · Nov 11, 2020 · national
CN 202011407911.8 · Dec 4, 2020 · national
CN 202011627733.X · Dec 31, 2020 · national
Continuity (3)
Continuation 19012024 · Jan 7, 2025
Division 18043508
Related Publication 20250243195A1 · Jul 31, 2025
References Cited (28)
US 12227499B2 · Yang · 2025 [cited by examiner]
US 20170342059A1 · Li et al. · 2017 [cited by applicant]
US 20230126875A1 · Yang et al. · 2023 [cited by applicant]
US 20230295154A1 · Meng et al. · 2023 [cited by applicant]
US 20230322756A1 · Yang et al. · 2023 [cited by applicant]
US 20240246958A1 · Yang et al. · 2024 [cited by applicant]
AU 2022321506A1 · 2024 [cited by applicant]
EA 023430B1 · 2016 [cited by applicant]
RU 2694899C9 · 2019 [cited by applicant]
WO WO2003099805A1 · 2003 [cited by applicant]
WO WO2009111700A2 · 2009 [cited by applicant]
WO WO2010114824A1 · 2010 [cited by applicant]
WO WO2018056453A1 · 2018 [cited by applicant]
WO WO2018109607A1 · 2018 [cited by applicant]
WO WO2019239319A1 · 2019 [cited by applicant]
WO WO2020103815A1 · 2020 [cited by applicant]
WO WO2021219019A1 · 2021 [cited by applicant]
WO WO2022007979A1 · 2022 [cited by applicant]
WO WO2022040600A1 · 2022 [cited by applicant]
WO WO2022078380A1 · 2022 [cited by applicant]
WO WO2022078407A1 · 2022 [cited by applicant]
WO WO2022199661A1 · 2022 [cited by applicant]
WO WO2022228490A1 · 2022 [cited by applicant]
WO WO2023011539A1 · 2023 [cited by applicant]
US 12,215,103 B2, 02/2025, Yang (withdrawn) [cited by examiner]
U.S. Appl. No. 19/012,024, filed Jan. 7, 2025, Yang et al. [cited by applicant]
Intemational Search Report issued Nov. 30, 2021 in PCT/CN2021/115915. [cited by applicant]
Kummerer, K., Pharmaceuticals in the Environment, Annual Review of Environment and Resources, 35:57-75 (2010). [cited by applicant]